Complera FDA Approval History
FDA Approved: Yes (First approved August 10, 2011)
Brand name: Complera
Generic name: emtricitabine, rilpivirine and tenofovir disoproxil fumarate
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: HIV Infection
Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is a combination of three antiretroviral medications indicated for the once daily treatment of HIV-1 infection in treatment-naïve adults.
Development timeline for Complera
| Date | Article |
|---|---|
| Aug 10, 2011 | Approval U.S. Food and Drug Administration Approves Gilead Sciences' Complera, a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve Adults |
See also
Complera (emtricitabine, rilpivirine and tenofovir disoproxil fumarate) Consumer information
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
